Global Myelodysplastic Syndrome Industry Research Report, Growth Trends and Competitive Analysis 2022-2028
Report Code: KNJ1408756 No. of Pages: 130 Category: Pharmaceuticals and Healthcare
Publisher: Date of Publish:
Publisher: Date of Publish:
Report Overview Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Myelodysplastic Syndrome estimated at in the year 2022, is projected to reach a revised size of by 2028, growing at a CAGR of during the forecast period 2022-2028. The USA market for Myelodysplastic Syndrome is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028. The China market for Myelodysplastic Syndrome is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028. The Europe market for Myelodysplastic Syndrome is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028. The global key companies of Myelodysplastic Syndrome include Celgene, Novartis, Otsuka, Actinium Pharmaceuticals, Acceleron Pharma, Bellicum Pharmaceuticals, Cornerstone Pharmaceuticals, CTI BioPharma and Onconova Therapeutics, etc. In 2021, the global top five players had a share approximately % in terms of revenue. Report Scope This latest report researches the industry structure, revenue and gross margin. Major players’ headquarters, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Myelodysplastic Syndrome companies, distributors, end users, industry associations, governments' industry bureaus, industry publications, industry experts, third party database, and our in-house databases. This report also includes a discussion of the major players across each regional Myelodysplastic Syndrome market. Further, it explains the major drivers and regional dynamics of the global Myelodysplastic Syndrome market and current trends within the industry. Key Companies Covered In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable revenue, market share and rank data of the companies for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report: Celgene Novartis Otsuka Actinium Pharmaceuticals Acceleron Pharma Bellicum Pharmaceuticals Cornerstone Pharmaceuticals CTI BioPharma Onconova Therapeutics Strategia Therapeutics KaloBios Pharmaceuticals Kiadis Pharma Mirati Therapeutics Astex Celator Pharmaceuticals Eli-lilly Sunesis Pharmaceuticals Targazyme Gamida Cell GlaxoSmithKline Sumitomo Dainippon Pharma TetraLogic Pharmaceuticals Market Segments This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides revenue forecast data by type and by application segments based on value for the period 2017-2028. Myelodysplastic Syndrome Segment by Type Alkylating Agents Cytotoxic Antibiotics Topoisomerase Inhibitors Others Myelodysplastic Syndrome Segment by Application Hospital Clinic Key Regions & Countries This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value data of each region and country for the period 2017-2028. North America United States Canada Europe Germany France UK Italy Russia Nordic Countries Rest of Europe Asia-Pacific China Japan South Korea Southeast Asia India Australia Rest of Asia Latin America Mexico Brazil Rest of Latin America Middle East & Africa Turkey Saudi Arabia UAE Rest of MEA Key Drivers & Barriers High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects. COVID-19 and Russia-Ukraine War Influence Analysis The readers in the section will understand how the Myelodysplastic Syndrome market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
1 Report Overview 1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global Myelodysplastic Syndrome Market Size Growth Rate by Type: 2017 VS 2021 VS 2028 1.2.2 Alkylating Agents 1.2.3 Cytotoxic Antibiotics 1.2.4 Topoisomerase Inhibitors 1.2.5 Others 1.3 Market by Application 1.3.1 Global Myelodysplastic Syndrome Market Growth Rate by Application: 2017 VS 2021 VS 2028 1.3.2 Hospital 1.3.3 Clinic 1.4 Study Objectives 1.5 Years Considered 2 Market Perspective 2.1 Global Myelodysplastic Syndrome Market Size (2017-2028) 2.2 Myelodysplastic Syndrome Market Size across Key Geographies Worldwide: 2017 VS 2021 VS 2028 2.3 Global Myelodysplastic Syndrome Market Size by Region (2017-2022) 2.4 Global Myelodysplastic Syndrome Market Size Forecast by Region (2023-2028) 2.5 Global Top Myelodysplastic Syndrome Countries Ranking by Market Size 3 Myelodysplastic Syndrome Competitive by Company 3.1 Global Myelodysplastic Syndrome Revenue by Players 3.1.1 Global Myelodysplastic Syndrome Revenue by Players (2017-2022) 3.1.2 Global Myelodysplastic Syndrome Market Share by Players (2017-2022) 3.2 Global Myelodysplastic Syndrome Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 3.3 Company Covered: Ranking by Myelodysplastic Syndrome Revenue 3.4 Global Myelodysplastic Syndrome Market Concentration Ratio 3.4.1 Global Myelodysplastic Syndrome Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Top 10 and Top 5 Companies by Myelodysplastic Syndrome Revenue in 2021 3.5 Global Myelodysplastic Syndrome Key Players Head office and Area Served 3.6 Key Players Myelodysplastic Syndrome Product Solution and Service 3.7 Date of Enter into Myelodysplastic Syndrome Market 3.8 Mergers & Acquisitions, Expansion Plans 4 Global Myelodysplastic Syndrome Breakdown Data by Type 4.1 Global Myelodysplastic Syndrome Historic Revenue by Type (2017-2022) 4.2 Global Myelodysplastic Syndrome Forecasted Revenue by Type (2023-2028) 5 Global Myelodysplastic Syndrome Breakdown Data by Application 5.1 Global Myelodysplastic Syndrome Historic Market Size by Application (2017-2022) 5.2 Global Myelodysplastic Syndrome Forecasted Market Size by Application (2023-2028) 6 North America 6.1 North America Myelodysplastic Syndrome Revenue by Company (2020-2022) 6.2 North America Myelodysplastic Syndrome Revenue by Type (2017-2028) 6.3 North America Myelodysplastic Syndrome Revenue by Application (2017-2028) 6.4 North America Myelodysplastic Syndrome Revenue by Country (2017-2028) 6.4.1 U.S. 6.4.2 Canada 7 Europe 7.1 Europe Myelodysplastic Syndrome Revenue by Company (2020-2022) 7.2 Europe Myelodysplastic Syndrome Revenue by Type (2017-2028) 7.3 Europe Myelodysplastic Syndrome Revenue by Application (2017-2028) 7.4 Europe Myelodysplastic Syndrome Revenue by Country (2017-2028) 7.4.1 Germany 7.4.2 France 7.4.3 U.K. 7.4.4 Italy 7.4.5 Russia 8 Asia Pacific 8.1 Asia Pacific Myelodysplastic Syndrome Revenue by Company (2020-2022) 8.2 Asia Pacific Myelodysplastic Syndrome Revenue by Type (2017-2028) 8.3 Asia Pacific Myelodysplastic Syndrome Revenue by Application (2017-2028) 8.4 Asia Pacific Myelodysplastic Syndrome Revenue by Region (2017-2028) 8.4.1 China 8.4.2 Japan 8.4.3 South Korea 8.4.4 India 8.4.5 Australia 8.4.6 Taiwan 8.4.7 Indonesia 8.4.8 Thailand 8.4.9 Malaysia 8.4.10 Philippines 8.4.11 Vietnam 9 Latin America 9.1 Latin America Myelodysplastic Syndrome Revenue by Company (2020-2022) 9.2 Latin America Myelodysplastic Syndrome Revenue by Type (2017-2028) 9.3 Latin America Myelodysplastic Syndrome Revenue by Application (2017-2028) 9.4 Latin America Myelodysplastic Syndrome Revenue by Country (2017-2028) 9.4.1 Mexico 9.4.2 Brazil 9.4.3 Argentina 10 Middle East and Africa 10.1 Middle East and Africa Myelodysplastic Syndrome Revenue by Company (2020-2022) 10.2 Middle East and Africa Myelodysplastic Syndrome Revenue by Type (2017-2028) 10.3 Middle East and Africa Myelodysplastic Syndrome Revenue by Application (2017-2028) 10.4 Middle East and Africa Myelodysplastic Syndrome Revenue by Country (2017-2028) 10.4.1 Turkey 10.4.2 Saudi Arabia 10.4.3 UAE 11 Company Profiles 11.1 Celgene 11.1.1 Celgene Company Details 11.1.2 Celgene Business Overview 11.1.3 Celgene Myelodysplastic Syndrome Products and Services 11.1.4 Celgene Myelodysplastic Syndrome Revenue in Myelodysplastic Syndrome Business (2017-2022) 11.1.5 Celgene Myelodysplastic Syndrome SWOT Analysis 11.1.6 Celgene Recent Developments 11.2 Novartis 11.2.1 Novartis Company Details 11.2.2 Novartis Business Overview 11.2.3 Novartis Myelodysplastic Syndrome Products and Services 11.2.4 Novartis Myelodysplastic Syndrome Revenue in Myelodysplastic Syndrome Business (2017-2022) 11.2.5 Novartis Myelodysplastic Syndrome SWOT Analysis 11.2.6 Novartis Recent Developments 11.3 Otsuka 11.3.1 Otsuka Company Details 11.3.2 Otsuka Business Overview 11.3.3 Otsuka Myelodysplastic Syndrome Products and Services 11.3.4 Otsuka Myelodysplastic Syndrome Revenue in Myelodysplastic Syndrome Business (2017-2022) 11.3.5 Otsuka Myelodysplastic Syndrome SWOT Analysis 11.3.6 Otsuka Recent Developments 11.4 Actinium Pharmaceuticals 11.4.1 Actinium Pharmaceuticals Company Details 11.4.2 Actinium Pharmaceuticals Business Overview 11.4.3 Actinium Pharmaceuticals Myelodysplastic Syndrome Products and Services 11.4.4 Actinium Pharmaceuticals Myelodysplastic Syndrome Revenue in Myelodysplastic Syndrome Business (2017-2022) 11.4.5 Actinium Pharmaceuticals Myelodysplastic Syndrome SWOT Analysis 11.4.6 Actinium Pharmaceuticals Recent Developments 11.5 Acceleron Pharma 11.5.1 Acceleron Pharma Company Details 11.5.2 Acceleron Pharma Business Overview 11.5.3 Acceleron Pharma Myelodysplastic Syndrome Products and Services 11.5.4 Acceleron Pharma Myelodysplastic Syndrome Revenue in Myelodysplastic Syndrome Business (2017-2022) 11.5.5 Acceleron Pharma Myelodysplastic Syndrome SWOT Analysis 11.5.6 Acceleron Pharma Recent Developments 11.6 Bellicum Pharmaceuticals 11.6.1 Bellicum Pharmaceuticals Company Details 11.6.2 Bellicum Pharmaceuticals Business Overview 11.6.3 Bellicum Pharmaceuticals Myelodysplastic Syndrome Products and Services 11.6.4 Bellicum Pharmaceuticals Myelodysplastic Syndrome Revenue in Myelodysplastic Syndrome Business (2017-2022) 11.6.5 Bellicum Pharmaceuticals Myelodysplastic Syndrome SWOT Analysis 11.6.6 Bellicum Pharmaceuticals Recent Developments 11.7 Cornerstone Pharmaceuticals 11.7.1 Cornerstone Pharmaceuticals Company Details 11.7.2 Cornerstone Pharmaceuticals Business Overview 11.7.3 Cornerstone Pharmaceuticals Myelodysplastic Syndrome Products and Services 11.7.4 Cornerstone Pharmaceuticals Myelodysplastic Syndrome Revenue in Myelodysplastic Syndrome Business (2017-2022) 11.7.5 Cornerstone Pharmaceuticals Myelodysplastic Syndrome SWOT Analysis 11.7.6 Cornerstone Pharmaceuticals Recent Developments 11.8 CTI BioPharma 11.8.1 CTI BioPharma Company Details 11.8.2 CTI BioPharma Business Overview 11.8.3 CTI BioPharma Myelodysplastic Syndrome Products and Services 11.8.4 CTI BioPharma Myelodysplastic Syndrome Revenue in Myelodysplastic Syndrome Business (2017-2022) 11.8.5 CTI BioPharma Myelodysplastic Syndrome SWOT Analysis 11.8.6 CTI BioPharma Recent Developments 11.9 Onconova Therapeutics 11.9.1 Onconova Therapeutics Company Details 11.9.2 Onconova Therapeutics Business Overview 11.9.3 Onconova Therapeutics Myelodysplastic Syndrome Products and Services 11.9.4 Onconova Therapeutics Myelodysplastic Syndrome Revenue in Myelodysplastic Syndrome Business (2017-2022) 11.9.5 Onconova Therapeutics Myelodysplastic Syndrome SWOT Analysis 11.9.6 Onconova Therapeutics Recent Developments 11.10 Strategia Therapeutics 11.10.1 Strategia Therapeutics Company Details 11.10.2 Strategia Therapeutics Business Overview 11.10.3 Strategia Therapeutics Myelodysplastic Syndrome Products and Services 11.10.4 Strategia Therapeutics Myelodysplastic Syndrome Revenue in Myelodysplastic Syndrome Business (2017-2022) 11.10.5 Strategia Therapeutics Myelodysplastic Syndrome SWOT Analysis 11.10.6 Strategia Therapeutics Recent Developments 11.11 KaloBios Pharmaceuticals 11.11.1 KaloBios Pharmaceuticals Company Details 11.11.2 KaloBios Pharmaceuticals Business Overview 11.11.3 KaloBios Pharmaceuticals Myelodysplastic Syndrome Products and Services 11.11.4 KaloBios Pharmaceuticals Myelodysplastic Syndrome Revenue in Myelodysplastic Syndrome Business (2017-2022) 11.11.5 KaloBios Pharmaceuticals Recent Developments 11.12 Kiadis Pharma 11.12.1 Kiadis Pharma Company Details 11.12.2 Kiadis Pharma Business Overview 11.12.3 Kiadis Pharma Myelodysplastic Syndrome Products and Services 11.12.4 Kiadis Pharma Myelodysplastic Syndrome Revenue in Myelodysplastic Syndrome Business (2017-2022) 11.12.5 Kiadis Pharma Recent Developments 11.13 Mirati Therapeutics 11.13.1 Mirati Therapeutics Company Details 11.13.2 Mirati Therapeutics Business Overview 11.13.3 Mirati Therapeutics Myelodysplastic Syndrome Products and Services 11.13.4 Mirati Therapeutics Myelodysplastic Syndrome Revenue in Myelodysplastic Syndrome Business (2017-2022) 11.13.5 Mirati Therapeutics Recent Developments 11.14 Astex 11.14.1 Astex Company Details 11.14.2 Astex Business Overview 11.14.3 Astex Myelodysplastic Syndrome Products and Services 11.14.4 Astex Myelodysplastic Syndrome Revenue in Myelodysplastic Syndrome Business (2017-2022) 11.14.5 Astex Recent Developments 11.15 Celator Pharmaceuticals 11.15.1 Celator Pharmaceuticals Company Details 11.15.2 Celator Pharmaceuticals Business Overview 11.15.3 Celator Pharmaceuticals Myelodysplastic Syndrome Products and Services 11.15.4 Celator Pharmaceuticals Myelodysplastic Syndrome Revenue in Myelodysplastic Syndrome Business (2017-2022) 11.15.5 Celator Pharmaceuticals Recent Developments 11.16 Eli-lilly 11.16.1 Eli-lilly Company Details 11.16.2 Eli-lilly Business Overview 11.16.3 Eli-lilly Myelodysplastic Syndrome Products and Services 11.16.4 Eli-lilly Myelodysplastic Syndrome Revenue in Myelodysplastic Syndrome Business (2017-2022) 11.16.5 Eli-lilly Recent Developments 11.17 Sunesis Pharmaceuticals 11.17.1 Sunesis Pharmaceuticals Company Details 11.17.2 Sunesis Pharmaceuticals Business Overview 11.17.3 Sunesis Pharmaceuticals Myelodysplastic Syndrome Products and Services 11.17.4 Sunesis Pharmaceuticals Myelodysplastic Syndrome Revenue in Myelodysplastic Syndrome Business (2017-2022) 11.17.5 Sunesis Pharmaceuticals Recent Developments 11.18 Targazyme 11.18.1 Targazyme Company Details 11.18.2 Targazyme Business Overview 11.18.3 Targazyme Myelodysplastic Syndrome Products and Services 11.18.4 Targazyme Myelodysplastic Syndrome Revenue in Myelodysplastic Syndrome Business (2017-2022) 11.18.5 Targazyme Recent Developments 11.19 Gamida Cell 11.19.1 Gamida Cell Company Details 11.19.2 Gamida Cell Business Overview 11.19.3 Gamida Cell Myelodysplastic Syndrome Products and Services 11.19.4 Gamida Cell Myelodysplastic Syndrome Revenue in Myelodysplastic Syndrome Business (2017-2022) 11.19.5 Gamida Cell Recent Developments 11.20 GlaxoSmithKline 11.20.1 GlaxoSmithKline Company Details 11.20.2 GlaxoSmithKline Business Overview 11.20.3 GlaxoSmithKline Myelodysplastic Syndrome Products and Services 11.20.4 GlaxoSmithKline Myelodysplastic Syndrome Revenue in Myelodysplastic Syndrome Business (2017-2022) 11.20.5 GlaxoSmithKline Recent Developments 11.21 Sumitomo Dainippon Pharma 11.21.1 Sumitomo Dainippon Pharma Company Details 11.21.2 Sumitomo Dainippon Pharma Business Overview 11.21.3 Sumitomo Dainippon Pharma Myelodysplastic Syndrome Products and Services 11.21.4 Sumitomo Dainippon Pharma Myelodysplastic Syndrome Revenue in Myelodysplastic Syndrome Business (2017-2022) 11.21.5 Sumitomo Dainippon Pharma Recent Developments 11.22 TetraLogic Pharmaceuticals 11.22.1 TetraLogic Pharmaceuticals Company Details 11.22.2 TetraLogic Pharmaceuticals Business Overview 11.22.3 TetraLogic Pharmaceuticals Myelodysplastic Syndrome Products and Services 11.22.4 TetraLogic Pharmaceuticals Myelodysplastic Syndrome Revenue in Myelodysplastic Syndrome Business (2017-2022) 11.22.5 TetraLogic Pharmaceuticals Recent Developments 12 Myelodysplastic Syndrome Market Dynamics 12.1 Myelodysplastic Syndrome Market Trends 12.2 Myelodysplastic Syndrome Market Drivers 12.3 Myelodysplastic Syndrome Market Challenges 12.4 Myelodysplastic Syndrome Market Restraints 13 Research Findings and Conclusion 14 Appendix 14.1 Research Methodology 14.1.1 Methodology/Research Approach 14.1.2 Data Source 14.2 Author Details
NEED Help?
If you need any help or guidance, please feel free to call us.
USA : +1 (661) 636 6162
INDIA : +91 9325802062
or
Write us on : sales@kandjmarketresearch.com